Yifan Pharmaceutical: The drug registration application for Sodium Salbutamol Powder has been accepted
I'm PortAI, I can summarize articles.
Yifan Pharmaceutical announced that the drug registration application for its wholly-owned subsidiary Sichuan Defeng Pharmaceutical Co., Ltd.'s sodium sapropterin dihydrochloride granules has been accepted by the National Medical Products Administration. This drug is suitable for reducing blood phenylalanine levels in patients with tetrahydrobiopterin-responsive phenylketonuria, applicable to adults and children over 1 month old. The application was submitted in September 2025 and has been accepted
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments